title: Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
abstract: Treatment of male lower urinary tract symptoms (LUTS) has traditionally focused on the management of benign prostatic obstruction, but the contribution of bladder dysfunction has been recently recognized. Therefore, it is well understood that LUTS have multifactorial etiology and often occur in clusters and not in isolation. Voiding LUTS are highly prevalent in men, but storage LUTS have been proved to be more bothersome. α1-Blockers are the most widely used pharmacologic agents for the treatment of symptoms relating to benign prostatic enlargement due to benign prostatic hyperplasia (BPH), while antimuscarinics are the drug class of choice for overactive bladder symptoms. A combination of the two drug classes would be a reasonable approach to treat men with both storage and voiding symptoms, and several short-term studies have proved the efficacy and safety of different combinations with an α1-blocker and an antimuscarinic. Following previous studies on the separate administration of solifenacin and tamsulosin, a fixed-dose combination tablet of tamsulosin oral controlled absorption system (OCAS) 0.4 mg and solifenacin succinate 6 mg has been recently introduced, and the current review evaluates the available data on the use of this fixed-dose combination in the treatment of LUTS in men with BPH.
authors.affiliation: Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Dimitropoulos
authors.affiliation: Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
authors.forename: Stavros
authors.initials: S
authors.lastname: Gravas
mesh_terms: D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy*; D000069464:Solifenacin Succinate / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000077409:Tamsulosin
chemical_list: D013449:Sulfonamides; D000077409:Tamsulosin; D000069464:Solifenacin Succinate
keywords: benign prostatic hyperplasia; benign prostatic obstruction; fixed-dose combination; lower urinary tract symptoms; overactive bladder; solifenacin; tamsulosin
references.citation: Eur Urol. 2013 Dec;64(6):1003-12
references.pmid: 23932438
references.citation: Eur Urol. 2013 Sep;64(3):398-407
references.pmid: 23537687
references.citation: Urol Int. 2012;88(2):177-82
references.pmid: 22179115
references.citation: J Auton Pharmacol. 1996 Feb;16(1):21-8
references.pmid: 8736427
references.citation: Urology. 2003 Jan;61(1):37-49
references.pmid: 12559262
references.citation: Urology. 2011 Jul;78(1):126-33
references.pmid: 21601248
references.citation: Eur J Clin Pharmacol. 1998 Jun;54(4):367-73
references.pmid: 9696967
references.citation: BJU Int. 2007 Nov;100(5):987-1006
references.pmid: 17922784
references.citation: J Pharmacol Sci. 2010;112(2):151-7
references.pmid: 20134112
references.citation: J Urol. 1998 Sep;160(3 Pt 1):784-91
references.pmid: 9720548
references.citation: BJU Int. 2009 Apr;103 Suppl 3:12-23
references.pmid: 19302498
references.citation: Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
references.pmid: 17049716
references.citation: J Urol. 1997 Mar;157(3):885-9
references.pmid: 9072592
references.citation: Eur Urol. 2006 Apr;49(4):651-8
references.pmid: 16530611
references.citation: Urology. 2001 Dec;58(6 Suppl 1):5-16; discussion 16
references.pmid: 11750242
references.citation: Eur Urol. 2013 Jan;63(1):158-65
references.pmid: 22831853
references.citation: J Urol. 2005 Dec;174(6):2273-5. discussion 2275-6
references.pmid: 16280803
references.citation: BJU Int. 2008 Aug;102(4):470-4
references.pmid: 18476974
references.citation: BJU Int. 2008 Feb;101(3):319-24
references.pmid: 18005199
references.citation: Int Urol Nephrol. 2014 Mar;46(3):523-9
references.pmid: 24097273
references.citation: BJU Int. 2009 Apr;103 Suppl 3:48-57
references.pmid: 19302502
references.citation: Pharmacol Rev. 2001 Jun;53(2):319-56
references.pmid: 11356987
references.citation: Clin Interv Aging. 2014;9:1021-30
references.pmid: 25031529
references.citation: Biol Pharm Bull. 2007 Jan;30(1):54-8
references.pmid: 17202659
references.citation: Int J Urol. 2006 Oct;13(10):1311-6
references.pmid: 17010010
references.citation: Int J Clin Pract. 2008 May;62(5):688-94
references.pmid: 18355237
references.citation: Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119
references.pmid: 16465187
references.citation: J Urol. 2009 May;181(5):2214-21; discussion 2221-2
references.pmid: 19296986
references.citation: Drugs Aging. 2012 May 1;29(5):405-19
references.pmid: 22550968
references.citation: Lancet Neurol. 2004 Jan;3(1):46-53
references.pmid: 14693111
references.citation: Urology. 2003 Jul;62(1):1-9
references.pmid: 12837408
references.citation: Urology. 2003 Nov;62(5 Suppl 2):3-10
references.pmid: 14662401
references.citation: BMC Health Serv Res. 2007;7:55
references.pmid: 17439645
references.citation: J Cataract Refract Surg. 2005 Apr;31(4):664-73
references.pmid: 15899440
references.citation: Curr Opin Urol. 2009 Jan;19(1):49-54
references.pmid: 19057216
references.citation: Adv Urol. 2010;:205251
references.pmid: 20981257
references.citation: J Urol. 2009 Dec;182(6):2825-30
references.pmid: 19837435
references.citation: Neurourol Urodyn. 2008;27(3):226-30
references.pmid: 17638312
references.citation: Clin Pharmacokinet. 2009;48(5):281-302
references.pmid: 19566112
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):368-78
references.pmid: 15608083
references.citation: Drugs. 2006;66(3):287-301
references.pmid: 16526818
references.citation: J Urol. 2008 Jul;180(1):47-54
references.pmid: 18485378
references.citation: Eur Urol. 2008 Sep;54(3):563-9
references.pmid: 18423969
references.citation: Eur Urol. 2015 Feb;67(2):262-70
references.pmid: 25070148
references.citation: Eur Urol. 2010 Apr;57(4):586-91
references.pmid: 20036783
references.citation: Circulation. 1999 Dec 7;100(23):2336-43
references.pmid: 10587338
references.citation: Pharmacol Rev. 2004 Dec;56(4):581-631
references.pmid: 15602011
references.citation: J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004
references.pmid: 16469601
references.citation: Urol Int. 2014;93(3):338-43
references.pmid: 25171502
references.citation: Eur Urol. 2013 Jul;64(1):118-40
references.pmid: 23541338